Peter Traber - Galectin Therapeutics President CEO, Chief Medical Officer, Director
| GALT Stock | USD 3.38 0.02 0.59% |
CEO
Dr. Peter G. Traber, M.D., is no longer President, Chief Executive Officer, Chief Medical Officer of Galectin Therapeutics Inc. Dr. Traber also served as a director of the Company from 2009 through 2017. Dr. Traber is President Emeritus, and from 2003 to 2008 was President and Chief Executive Officer, of Baylor College of Medicine. From 2000 to 2003 he was Senior Vice President Clinical Development and Medical Affairs and Chief Medical Officer of GlaxoSmithKline plc. Dr. Traber was the Chairman of the Board and Chief Executive Officer of TerraSep, LLC, a Mountain View, CA biotechnology company. He also has served as Chief Executive Officer of the University of Pennsylvania Health System, as well as Chair of the Department of Internal Medicine and Chief of Gastroenterology for the University of Pennsylvania School of Medicine and was named as a director of NeoStem, Inc. in 2015
| Age | 61 |
| Address | 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071 |
| Phone | 678 620 3186 |
| Web | https://galectintherapeutics.com |
Galectin Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9617) % which means that it has lost $0.9617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (37.2795) %, meaning that it created substantial loss on money invested by shareholders. Galectin Therapeutics' management efficiency ratios could be used to measure how well Galectin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.53 in 2024. Return On Capital Employed is likely to gain to -2.89 in 2024. At this time, Galectin Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 76.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 14.9 M in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Joseph Reilly | Provident Bancorp | 66 | |
| David Mansfield | Provident Bancorp | 62 | |
Management Performance
| Return On Equity | -37.28 | ||||
| Return On Asset | -0.96 |
Galectin Therapeutics Leadership Team
Elected by the shareholders, the Galectin Therapeutics' board of directors comprises two types of representatives: Galectin Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galectin. The board's role is to monitor Galectin Therapeutics' management team and ensure that shareholders' interests are well served. Galectin Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galectin Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Rubin, Independent Director | ||
| CPA CPA, Treasurer CFO | ||
| Kevin Freeman, Independent Director | ||
| Jack CPA, Treasurer CFO | ||
| John Mauldin, Independent Director | ||
| Arthur Greenberg, Independent Director | ||
| Rex Horton, Executive Director - Regulatory Affairs and Quality Assurance | ||
| Jack Callicutt, CFO | ||
| James Czirr, Executive Chairman and Executive VP - Bus. Devel. | ||
| Joel Lewis, Independent Director | ||
| Eliezer Zomer, Executive Director of Product Devel. | ||
| Stephen Shulman, Independent Director | ||
| Steven Prelack, Independent Director | ||
| Kary Eldred, Independent Director | ||
| Gilbert Amelio, Independent Director | ||
| Richard Uihlein, Chairman of the Board | ||
| Gilbert Omenn, Director | ||
| Jeff Katstra, Head Development | ||
| Robert Tritt, General Counsel | ||
| Beth Knowles, Executive Manager | ||
| Peter Traber, President CEO, Chief Medical Officer, Director | ||
| Harold Shlevin, COO and Corporate Secretary | ||
| Adam Allgood, Executive Director of Clinical Development |
Galectin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galectin Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -37.28 | ||||
| Return On Asset | -0.96 | ||||
| Current Valuation | 290.41 M | ||||
| Shares Outstanding | 61.9 M | ||||
| Shares Owned By Insiders | 31.12 % | ||||
| Shares Owned By Institutions | 11.67 % | ||||
| Number Of Shares Shorted | 2.25 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (38.04 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Galectin Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Galectin Therapeutics' short interest history, or implied volatility extrapolated from Galectin Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Galectin Stock analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Galectin Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galectin Therapeutics. If investors know Galectin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Return On Assets (0.96) | Return On Equity (37.28) |
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galectin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.